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Introduction
A pandemic novel H1N1 influenza outbreak [the
pandemic (H1N1) 2009], starting from the United
States and Mexico, has spread worldwide since April
2009.1–3 A total of more than 1 million confirmed
cases with approximately 10,000 deaths have been re-
ported by the World Health Organization (WHO).
The sources of the novel rearranged virus are from
swine, avian and human influenza viruses.4,5 Young
people are susceptible to the infection, with occa-
sional deterioration of their clinical manifestations.6,7
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Seroprevalence of antibodies to H1N1 virus in hospital staff
The first imported case in Taiwan appeared in May
2009, and the epidemic spread to the community 
in July 2009.8 Healthcare workers, according to the
experience with the severe acute respiratory syndrome
(SARS) epidemic, have a higher risk of contracting
diseases,9,10 and belong to a unique risk group. The
vaccination campaign for the novel H1N1 influenza
virus is a national policy to protect people from viral
attack. To determine the prevaccination prevalence of
antibody levels against the novel H1N1 influenza, we
conducted surveillance of healthcare personnel in a
medical center.
Methods
Study design and case recruitment
A total of 295 serum samples were collected from
hospital staff, including doctors, nurses, students, and
administrative personnel, and 244 serum samples were
collected from people who came for physical check-up
between October 23, 2009 and November 20, 2009
before the vaccination campaign. The Institutional
Review Board of Taipei Veterans General Hospital
approved the protocol for this study.
Reagents for the hemagglutination-inhibition
(HI) test
The preparation of the test sera was as follows: 100 μL
of serum was mixed with 300 μL receptor destroying
enzyme (RDE; Denka Seiken Co. Ltd., Tokyo, Japan)
at 37°C for 18–20 hours to remove the interfering non-
specific receptors, and the reaction was stopped by
incubating the mixture at 56°C for 30 minutes. Then,
600 μL of phosphate-buffered saline (PBS) was mixed
with RDE-treated serum to generate a 10-fold diluted
solution. Next, 50 μL of packed guinea pig red blood
cells (GP-RBC) were added to the solution for 1–2
hours at 4°C to remove nonspecific hemagglutination
activity.
The GP-RBC suspension was prepared as follows:
approximately 10 mL of guinea pig blood was obtained
and thoroughly mixed with a 1:4 ratio of Alsever’s solu-
tion (anticoagulant). The GP-RBC suspension was fil-
trated through sterile 2-layered gauze and washed
with PBS (pH 7.2) 3 times and then diluted with PBS
to form a 10% RBC stock suspension. RBC 0.75%
working suspension was prepared for the hemaggluti-
nation (HA) or HI tests.
HA and HI tests
Martin-Darby canine kidney (MDCK) cells were culti-
vated in 5% fetal calf serum (Biological Industries Ltd.,
Kibbutz Beit Haemek, Israel) and infected with in-
fluenza virus [strain A/Taiwan/T1338/2009 (H1N1),
A/Califormia/4/2009-like, kindly provided by Dr 
Yi-Ming A. Chen]; the virus was inactivated before
use. The culture supernatant was 2-fold serially diluted
with PBS (pH 7.2) in U-plates, followed by adding
50 μL of 0.75% GP-RBC suspension into each well of
a 96-well plate that contained equal volume (50 μL)
of serially diluted supernatant. The plate was covered
and left for 1 hour at room temperature. HA titers
were defined as the reciprocal of the highest dilution
that showed completely hemagglutination of the GP-
RBC. The HI test was conducted by mixing with an
equal volume (25 μL) of 2-fold serially diluted RDE-
treated serum and 8-HA unit viral antigen in each
well of a 96-well plate. After gentle shaking, 50 μL of
0.75% GP-RBC was added into each well of the plate.
The plate was covered and left for 1 hour at room
temperature. HI titers were defined as the reciprocal
of the highest dilution that completely inhibited hemag-
glutination of the GP-RBC. HI titer ≥ 40 was inter-
preted as positive. The geometric mean titer (GMT) is
defined as the geometric mean of the positive HI titers.
The seropositive rate (SPR) is defined as the percentage
of HI titers ≥ 40.
Statistical analysis
The χ2 test was used to compare differences in dis-
crete variables, and Student’s t test or Mann-Whitney
rank sum test was used to analyze the continuous
variables such as age and HI titers as appropriate. All
analyses were performed with SPSS version 17 (SPSS
Inc., Chicago, IL, USA). A p value < 0.05 was consid-
ered statistically significant.
Results
A total of 295 hospital staff and 244 control cases
(control group) were tested. The mean ages and 
sex ratio of the 2 groups are shown in Table 1. With
HI ≥ 40 as the cut-off value for seropositivity, the 
SPR of the hospital staff was significantly higher than
that of the control group (20.0% vs. 2.9%, p < 0.001)
(Table 1).
To further delineate the possible role of close 
patient contact, the hospital staff were divided into
first-line risk personnel (group 1) that included 120 doc-
tors from the Division of Infectious Diseases, and
inpatient nurses and staff from the Emergency Depart-
ment, and second-line risk personnel (group 2) that
included 175 general medical doctors, laboratory
staff and administrative personnel. The SPR of group 1
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was significantly higher than that of group 2 (30.8%
vs. 12.6%, p < 0.001) (Table 1).
There was no statistically significant difference 
in GMT antibodies to H1N1 influenza virus between 
the hospital staff and control group (47.2 vs. 48.8,
p = 0.925) (Figure 1). There was also no significant
difference between groups 1 and 2 (47.4 vs. 46.8,
p = 0.962).
Discussion
Since April 2009, a novel rearranged H1N1 influenza
virus (originally referred to as the swine-origin influenza
virus) outbreak emerged from Mexico and the United
States, with rapid propagation to almost all over the
world over several months. The WHO issued a pan-
demic alarm in June 2009; this pandemic involved
200 more countries, with more than 1 million con-
firmed cases and 10,000 reported deaths.1,11 Initially,
the case mortality rate was thought to be high (approx-
imately 7% in Mexico), but it now appears that the
mortality rate is no more than that of seasonal
influenza.12 The case mortality rate estimated by the
Taiwan Center for Disease Control is approximately 1 in
10,000.8 The decline in the case mortality rate of the
novel H1N1 pandemic is not likely to be due to rapid
virus evolution as genetic analyses have not shown sig-
nificant mutations.5,6 Instead, stringent surveillance
for infected people may be identifying a greater num-
ber of mild cases. The same phenomenon has been
described in another swine-origin influenza outbreak
in 1976 in Fort Dix,13,14 where 230 positive cases were
diagnosed by serological survey but there were only
13 cases with clinical symptoms and 1 death. Our results
are consistent with the notion that by serological sur-
veillance, seropositive individuals can be identified
from certain risk groups, such as hospital staff.
Although there are specific antiviral agents available
for treatment, it is generally believed that the most
effective approach is through a vaccination campaign.15
Several studies have demonstrated the efficacy of vac-
cination to prevent mortality and hospitalization, and
recent studies have indicated that the 2009 H1N1
monovalent vaccine is immunogenic in both adults
and children.16–20 The adverse effects associated with
vaccination are mild to moderate.17,18,21 Before initi-
ating a massive vaccination campaign, it is imperative
to understand the seroepidemiology of the popula-
tion. Traditionally, the HI test is a standard to evalu-
ate the antibody response to influenza vaccination.
Since the novel H1N1 influenza virus has never circu-
lated among people and previous seasonal vaccination
offers limited cross-protection, the SPR should, theo-
retically, be low even after seasonal vaccination.22,23
However, there are certain risk groups that may con-
tract the disease. Myers et al found that swine workers
are at increased risk of being infected by swine-origin
influenza virus through close contact.24 Healthcare
workers are susceptible to infectious diseases and our
Table 1. Seropositivity rate (SPR) of antibodies to H1N1 influenza virus in hospital staff and control group
Total cases, n Male, n (%) Age (yr), mean ± SD HI titer ≥ 40, n (%)
Control 244 140 (57.6) 52.0 ± 12.6 7 (2.9)*
Hospital staff 295 72 (24.4) 36.9 ± 10.6 59 (20.0)*
Group 1 120 28 (23.3) 34.0 ± 9.0 37 (30.8)*†
Group 2 175 44 (25.1) 38.8 ± 11.2 22 (12.6)*†
In comparison with the control group for SPR (HI titer ≥ 40): *to control group, p < 0.001; †group 1 vs. group 2, p < 0.001. HI = hemagglutination-inhibition;
SPR = proportion with HI titer ≥ 1:40 as seropositivity rate for antibodies to H1N1 influenza virus.
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Figure 1. Level and geometric mean titer (GMT) of prevaccination
sera against the pandemic (H1N1) 2009 virus among hospital
staff and the control group. *Horizontal bars indicate the GMT of
antibodies to the H1N1 influenza virus of each group: there were
no significant differences among groups. The GMTs of each group
are: Control = 48.8; Hospital staff = 47.2; Group 1 = 47.4; Group
2 = 46.8. Samples with hemagglutination-inhibition (HI) titer < 40
were excluded in the calculation.
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results support that notion. Hospital-acquired out-
breaks were reported during the SARS epidemic.9,25,26
For the mild pandemic (H1N1) 2009, our hospital
issued guidelines for the use of personal protective
equipment, such as the wearing of surgical or higher-
level masks, gloves, and facial protection equipment.
A self-reporting system was also established to iden-
tify symptomatic individuals according to the clinical
definition set by the Taiwan Center for Disease Con-
trol, i.e. (1) fever > 38°C; (2) influenza-like symptoms,
such as cough, headache, general malaise etc.; (3)
exclusion of illnesses with definite diagnoses, such as
tonsillitis. In this study, the strikingly high SPR
among the hospital staff, especially first-line workers,
indicates that the symptoms were mostly mild or sub-
clinical. The lack of significant differences in GMTs
was not unexpected as the 2 groups had not yet been
vaccinated and their immune statuses were presum-
ably similar. However, the relatively low GMT levels
indicate that the exposed individuals with mild or vague
symptoms did not develop strong immune responses,
compared to vaccination which usually elicits a strong
immune response. Most of the recent studies on the
pandemic (H1N1) 2009 virus focused on the clinical
manifestations of symptomatic cases.6,27 However, the
scope of this pandemic may be even more extensive, as
admitted cases are likely to be the tip of the iceberg.
Most infected individuals, as our data show, probably
only have mild or even subclinical symptoms.
Since the infectious control policy is not as stringent
as that for the SARS epidemic, it may only prevent
severe illness by reducing the amount of viral exposure.
Personal protective equipment may not be sufficient
for a more virulent influenza virus with equal transmis-
sion power.
One of the limitations of this study is that the dis-
tribution of age and sex was not comparable between
the hospital staff and control group. However, the
subjects in the control group were significantly older
but with a much lower SPR, suggesting that the hos-
pital staff could be at an even higher risk of infection
if they had been selected on an age-matched basis.
Another limitation is that this study did not include
questionnaires to obtain recent contact or travel his-
tory of study subjects.
In the process of establishing vaccination policy and
which groups should be vaccinated first, it is impera-
tive to determine the relative risk of contracting the
disease for certain risk groups. Our data indicate that
hospital staff should be vaccinated as soon as possible
against the H1N1 influenza virus as they are at high
risk of contracting it. In addition, for prevaccination
surveillance, healthcare workers may serve as a target
group in whom early seroepidemiologic changes of
new emerging infectious diseases may be detected, and
vaccine efficacy evaluated. Furthermore, for those
who have already developed protective antibodies
against the pandemic (H1N1) 2009 virus, whether or
not a booster dose of vaccination is needed is debat-
able. Given that a relatively high proportion of certain
groups may have already developed protective anti-
bodies and given the mild nature of the pandemic
(H1N1) 2009 virus, the pros and cons of a massive
vaccination campaign deserve further investigation.
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